Itb-med Llc

This study tested a combination of an experimental drug (siplizumab), donor bone marrow cells, and mild chemotherapy in 4 kidney transplant patients. The goal was to see if this approach could help the body accept the new kidney without needing lifelong anti-rejection medication.…

This study tested a new medicine called TCD601 (Siplizumab) in people receiving a new kidney. The goal was to see if it is safer and works better than a standard treatment (rATG) to prevent the body from rejecting the new kidney. The study included 33 adults aged 18 to 70 who got…